Renovorx strengthens intellectual property (ip) portfolio with eighth us patent

Los altos, calif.--( business wire )--renovorx, inc. (nasdaq: rnxt), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced that on january 3, 2023 the united states patent and trademark office issued us patent number 11,541,211 broadly covering methods for treating cholangiocarcinoma (bile duct cancer) by selectively delivering one or more therapeutic agents into targeted regions of the bile duct. this is renovorx's eighth us patent.
RNXT Ratings Summary
RNXT Quant Ranking